

JENKINS
WILSON
TAYLOR
& HUNT

patent attorneys

October 20, 2006

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

BENTLEY J. OLIVE

*CHRIS PERKINS, PH.D.

**JAMES DALY IV, PH.D.

P. ASHLEY DARDEN

DAVID M. SIGMON

WESLEY A. SHEFFIELD

SCOTT C. MAYHEW

PATENT AGENT
JAY KLINCK

TECHNICAL SPECIALIST
AMY ODENBAUGH, PH.D.

*LICENSED ONLY IN CA

**LICENSED ONLY IN KY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/594,826 for
METHOD FOR TREATING AUTOIMMUNE DISEASES WITH
ANTIBODIES
Our Ref. No. 1408/6

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (1 page);
3. Copies of cited references (10 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although no fee is believed to be due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/omb

Enclosures

Customer No. 25297

tel 919.493.8000
fax 919.419.0383

Jenkins, Wilson, Taylor & Hunt, P.A.
JenkinsWilson.com


University Tower, Suite 1200 | 3100 Tower Boulevard | Durham, North Carolina 27707

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 20, 2006.

Oksana Buynitzky
Date of Signature:

October 20, 2006

IFW



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 20, 2006.

Oksana Buynitzky
Oksana Buynitzky
Date of Signature

October 20, 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lazarus et al.

Group Art Unit: Not Assigned

Serial No.: 10/594,826

Examiner: Not Assigned

Filed: September 28, 2006

Docket No.: 1408/6

For: METHOD FOR TREATING AUTOIMMUNE DISEASES WITH ANTIBODIES

INFORMATION DISCLOSURE STATEMENT

(Before the Later of a First Office Action or 3 Months from Filing Date)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Atty. Docket No.: 1408/6

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.


Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date:

10/20/2006

By:



Arles A. Taylor, Jr.
Registration No. 39,395

Customer No.: 25297

1408/6 AAT/omb

Enclosures



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 1408/6	Serial No. 10/594,826
List of Documents Cited by Applicant	Applicant(s): Lazarus et al.	
	Filing Date: September 28, 2006	Group TBA

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes No
	A	WO99/03495	01/28/1999	WIPO	Beth Israel Deaconess Medical Center, Inc.	
	B	WO02/40047	05/23/2002	WIPO	Canadian Blood Services	
	C	CA 2,253,058	02/03/2000	Canada	Altarex Corp.	
	D	WO02/076384	10/03/2002	WIPO	Altarex Corp.	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Attorney Docket No. 1408/6	Serial No. 10/594,826
	Applicant(s): Lazarus et al.	
	Filing Date: September 28, 2006	Group TBA

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	E	International Search Report, Written Opinion of the International Searching Authority and Notification of Transmittal of International Preliminary Report on Patentability corresponding to the International Patent Application No. PCT/CA2005/000472 dated July 28, 2006
	F	Aigner et al. <i>CD24 mediates rolling of breast carcinoma cells on P-selectin</i> <i>The FASEB Journal</i> , Vol. 12, (1998), pp. 1241-1251
	G	Kuter et al. <i>The reciprocal relationship of thrombopoietin (c-Mpl Ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit</i> <i>Blood</i> , Vol. 85, no. 10, (1995), pp. 2720-2730
	H	Ristamaki et al. <i>Serum CD44 in malignant lymphonoma: an association with treatment response</i> <i>Blood</i> , Vol. 84, no. 1, (1994), pp. 238-243
	I	Siragam et al. <i>Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?</i> <i>Journal of Clinical Investigation</i> , Vol. 115, no. 1, (2005), pp. 155-243
	J	Song et al. <i>Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG</i> <i>Blood</i> , Vol. 101, no. 9, (2003), pp. 3708-3713

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.